Amisano G, Fornasero S, Migliaretti G, et al. Diarrheagenic Escherichia coli in acute gastroenteritis in infants in North-West Italy[J]. New Microbiol, 2011, 34(1):45-51.
Guttman JA, Li Y, Wickham ME , et al. Attaching and effacing pathogen-induced tight junction disruption in vivo [J]. Cell Microbiol, 2006, 8(4):634-645.
[4]
Luo W, Donnenberg MS. Analysis of the function of enteropathogenic Escherichia coli EspB by random mutagenesis[J]. Infect Immun, 2006, 74(2):810-820.
[5]
Hartland EL, Daniell SJ, Delahay RM, et al. The type III protein translocation system of enteropathogenic Escherichia coli involves EspA-EspB protein interactions[J]. Mol Microbiol, 2000, 35(6):1483-1492.
[6]
Singh MP1, Shaw RK, Knutton S, et al. Identification of amino acid residues within the N-terminal domain of EspA that play a role in EspA filament biogenesis and function[J]. J Bacteriol, 2008, 190(6):2221-2226.
[7]
La Ragione RM1, Patel S, Maddison B, et al. Recombinant anti-EspA antibodies block Escherichia coli O157:H7-induced attaching and effacing lesions in vitro[J]. Microbes Infect,2006,8(2):426-433.
[8]
Kühne SA1, Hawes WS, La Ragione RM, et al. Isolation of recombinant antibodies against EspA and intimin of Escherichia coli O157:H7[J]. J Clin Microbiol,2004,42(7):2966-2976.
[9]
Yu Zhijian, Huang Zhen, Sao Chongwen, et al. Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71[J]. Arch Virol. 2013;158(5):1071-1077.
[10]
Fujimori M, Amano J, Taniguchi S. The genus Bifidobacterium for cancer gene therapy[J].Curr Opin Drug Discov Devel,2002, 5:200-203.
